This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Thadani, U. Articles by Roden, D. M. Search for Related Content PubMed PubMed Citation Articles by Thadani, U. Articles by Roden, D. M.

(Circulation. 1998;97:2295-2296.)
© 1998 American Heart Association, Inc.

Cardiovascular News

FDA Panel Report: January 1998

Udho Thadani, MD; ; Dan M. Roden, MD

From the University of Oklahoma Health Sciences Center, Tulsa (U.T.) and Vanderbilt University Medical Center, Nashville, Tenn (D.M.R.).

Correspondence to Dan M. Roden, MD, Vanderbilt University Medical Center, 532 Medical Research Bldg, Nashville, TN 37232-3304.

The Cardiovascular and Renal Advisory Panel of the FDA met January 27-28, 1998, to discuss (1) evaluation and use of intravenous inotropic agents in patients with heart failure; (2) liver function test abnormalities with a new AT₁ receptor blocker, tasosartan; and (3) the use of the platelet IIb/IIIa receptor blocker eptifibatide in syndromes of acute cardiac ischemia.

Intravenous Inotropic Agents for Heart Failure

Intravenous drugs for the treatment of heart failure historically have been approved after demonstration of acute dose-dependent hemodynamic effects in patients with heart failure. Recently, however, there appears to have been a marked increase in the intermittent or continuous use of intravenous inotropic agents for longer periods than originally anticipated, often without monitoring of cardiac rhythm. This practice has become prevalent despite recent trials with oral inotropic agents that have shown adverse effects on mortality and morbidity during long-term treatment and preclinical data presented to the committee that raised the possibility that intermittent exposure to intravenously administered positive inotropic agents may accelerate myocardial cell death. The committee therefore voted unanimously that short-term use of intravenous inotropic agents for decompensated heart failure should be approved if an improvement in symptoms, renal function, and/or hemodynamics (including patients after bypass surgery) can be shown. However, for prolonged intermittent or continuous intravenous use, an improvement in survival and symptoms should be demonstrated in a placebo-controlled trial. The committee unanimously recommended that labeling of intravenous positive inotropic agents be revised to reflect the following: (1) that these drugs are indicated for patients who are hospitalized with acutely decompensated . . . [Full Text of this Article]

This article has been cited by other articles:

				C. Opasich, A. Russo, R. Mingrone, M. Zambelli, and L. Tavazzi Intravenous inotropic agents in the intensive therapy unit: do they really make a difference? Eur J Heart Fail, March 1, 2000; 2(1): 7 - 11. [Abstract] [Full Text] [PDF]